The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Desai, Brijal M ^a   Villanueva, Jessie ^a   Nguyen, Thierry Thien K ^a   Lioni, Mercedes ^a   Xiao, Min ^a   Kong, Jun ^a   Krepler, Clemens ^a   Vultur, Adina ^a   Flaherty, Keith T ^b   Nathanson, Katherine L ^c   Smalley, Keiran S M ^d   Herlyn, Meenhard ^a  

^a WISTAR INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE 2; DINACICLIB; LIPOCORTIN 5; PLACEBO; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN P53; RETINOBLASTOMA PROTEIN; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER REGRESSION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BETA-CYCLODEXTRINS; BICYCLO COMPOUNDS, HETEROCYCLIC; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 2; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MICE; MICE, SCID; PYRIDINIUM COMPOUNDS; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84875082183     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059588     Document Type: Article

References (51)

1. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, et al. (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Research 62: 6997-7000.
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
3. Hodis E, Watson Ian R, Kryukov Gregory V, Arold Stefan T, Imielinski M, et al. (2012) A Landscape of Driver Mutations in Melanoma. Cell 150: 251-263.
4. Nikolaou VA, Stratigos AJ, Flaherty KT, Tsao H (2012) Melanoma: New Insights and New Therapies. The Journal of investigative dermatology.
5. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, et al. (2012) Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib. New England Journal of Medicine 366: 707-714.
6. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, et al. (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18: 683-695.
7. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973-977.
8. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, et al. (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468: 968-U370.
9. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, et al. (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480: 387-390.
10. Kudchadkar R, Paraiso KHT, Smalley KSM (2012) Targeting Mutant BRAF in Melanoma: Current Status and Future Development of Combination Therapy Strategies. The Cancer Journal 18: 124-131 110.1097/PPO.1090b1013e31824b31436e.
11. Soengas MS, Lowe SW, (2003) Apoptosis and melanoma chemoresistance. Oncogene 22: 3138-3151.
12. Avery-Kiejda K, Bowden N, Croft A, Scurr L, Kairupan C, et al. (2011) P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC cancer 11: 203.
13. Smalley KS, Contractor R, Haass NK, Kulp AN, Atilla-Gokcumen GE, et al. (2007) An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res 67: 209-217.
14. de Lange J, Ly L, Lodder K, Verlaan-de Vries M, Teunisse A, et al. (2012) Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma. Oncogene 31: 1105-1116.
15. Shapiro GI, (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24: 1770-1783.
16. Meyerson M, Enders GH, Wu CL, Su LK, Gorka C, et al. (1992) A family of human cdc2-related protein kinases. Embo J 11: 2909-2917.
17. Sausville EA, (2002) Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol Med 8: S32-37.
18. Mittnacht S, (1998) Control of pRB phosphorylation. Curr Opin Genet Dev 8: 21-27.
19. Nevins JR, (1998) Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ 9: 585-593.
20. Leone G, DeGregori J, Jakoi L, Cook JG, Nevins JR, (1999) Collaborative role of E2F transcriptional activity and G1 cyclindependent kinase activity in the induction of S phase. Proc Natl Acad Sci U S A 96: 6626-6631.
21. DeGregori J, Kowalik T, Nevins JR, (1995) Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol Cell Biol 15: 4215-4224.
22. Palancade B, Bensaude O, (2003) Investigating RNA polymerase II carboxyl-terminal domain (CTD) phosphorylation. Eur J Biochem 270: 3859-3870.
23. Meinhart A, Kamenski T, Hoeppner S, Baumli S, Cramer P, (2005) A structural perspective of CTD function. Genes Dev 19: 1401-1415.
24. Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, et al. (2004) Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6: 565-576.
25. Smalley KS, Brafford P, Haass NK, Brandner JM, Brown E, et al. (2005) Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am J Pathol 166: 1541-1554.
26. Brummelkamp TR, Bernards R, Agami R, (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 550-553.
27. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, et al. (2006) Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 19: 290-302.
28. Tsavachidou D, Coleman ML, Athanasiadis G, Li S, Licht JD, et al. (2004) SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant. Cancer Res 64: 5556-5559.
29. Spittle C, Ward MR, Nathanson KL, Gimotty PA, Rappaport E, et al. (2007) Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn 9: 464-471.
30. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, et al. (2006) Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5: 1136-1144.
31. Jordan JJ, Inga A, Conway K, Edmiston S, Carey LA, et al. (2010) Altered-Function p53 Missense Mutations Identified in Breast Cancers Can Have Subtle Effects on Transactivation. Molecular Cancer Research 8: 701-716.
32. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, et al. (2012) Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. New England Journal of Medicine 367: 107-114.
33. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436: 117-122.
34. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819.
35. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, et al. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467: 596-599.
36. Tsai J, Lee JT, Wang W, Zhang J, Cho H, et al. (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proceedings of the National Academy of Sciences 105: 3041-3046.
37. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439: 358-362.
38. Ikediobi ON, Reimers M, Durinck S, Blower PE, Futreal AP, et al. (2008) In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation. Mol Cancer Ther.
39. Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, et al. (2008) The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 14: 230-239.
40. Kitada S, Zapata JM, Andreeff M, Reed JC, (2000) Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 96: 393-397.
41. Emanuel PO, Phelps RG, Mudgil A, Shafir M, Burstein DE, (2008) Immunohistochemical detection of XIAP in melanoma. J Cutan Pathol 35: 292-297.
42. McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, et al. (2002) Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109: 707-718.
43. Verhaegen M, Bauer JA, Martin de la Vega C, Wang G, Wolter KG, et al. (2006) A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 66: 11348-11359.
44. Polsky D, Bastian BC, Hazan C, Melzer K, Pack J, et al. (2001) HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res 61: 7642-7646.
45. Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, et al. (2012) MDM4 is a key therapeutic target in cutaneous melanoma. Nature medicine.
46. Ji Z, Njauw C, Taylor M, Neel V, Flaherty K, et al. (2012) p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. The Journal of investigative dermatology 132: 356-364.
47. Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-Laguna I, et al. (2011) Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biology & Therapy 12: 598-609.
48. Fu W, Ma L, Chu B, Wang X, Bui MM, et al. (2011) The Cyclin-Dependent Kinase Inhibitor SCH 727965 (Dinacliclib) Induces the Apoptosis of Osteosarcoma Cells. Molecular Cancer Therapeutics 10: 1018-1027.
49. Abdullah C, Wang X, Becker D, (2011) Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma. Cell Cycle 10: 977-988.
50. Lao CD, Moon J, Fruehauf JP, Flaherty LE, Bury MJ, et al. (2012) SWOG S0826: A phase II trial of SCH 727965 (NSC 747135) in patients with stage IV melanoma. Journal of Clinical Oncology 30.
51. Ambrosini G, Seelman SL, Qin LX, Schwartz GK, (2008) The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner. Cancer Res 68: 2312-2320.